Specialty Chemicals company Anupam Rasayan India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total revenue for Q4FY25 was at Rs 5,057 million as compared to Rs 4,130 million in Q4FY24; up 22% YoY. EBITDA (incl. other income) was at Rs 1,500 million in Q4FY25 as compared to Rs 1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter. Profit After Tax was at Rs 629 million in Q4FY25 as compared to Rs 405 million in Q4FY24; up 56% YoY. FY25 Financial Highlights: Total revenue for FY25 was at Rs 14,485 million as compared to Rs 15,053 million in FY24; down 4% YoY. EBITDA (incl. other income) was at Rs 4,123 million in FY25 as compared to Rs 4,109 million in FY24, this would translate into 28% EBITDA margin in FY25. Profit After Tax was at Rs 1,600 million in FY25 as compared to Rs 1,674 million in FY24. Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at Rs 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix. While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.” Result PDF